BPC-157 vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | Exenatide |
|---|---|---|
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |